Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB

Saverio De Lorenzo, Jan Wilem Alffenaar, Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Simon Tiberi, Mathieu S. Bolhuis, Richard Van Altena, Piero Viggiani, Andrea Piana, Antonio Spanevello, Giovanni Battista Migliori

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Clinical experience on meropenem-clavulanate to treat tuberculosis (TB) is anecdotal (according to case reports on 10 patients). The aim of our case-control study was to evaluate the contribution of meropenem-clavulanate when added to linezolid-containing regimens in terms of efficacy and safety/tolerability in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases after 3 months of second-line treatment. 37 cases with MDR-/XDR-TB were prescribed meropenem-clavulanate (3 g daily dose) in addition to a linezolid-containing regimen (dosage range 300-1200 mg·day-1 ), designed according to international guidelines, which was prescribed to 61 controls. The clinical severity of cases was worse than that of controls (drug susceptibility profile, proportion of sputum-smear positive and of re-treatment cases). The group of cases yielded a higher proportion of sputum-smear converters (28 (87.5%) out of 32 versus nine (56.3%) out of 16; p=0.02) and culture converters (31 (83.8%) out of 37 versus 15 (62.5%) out of 24; p=0.06). Excluding XDR-TB patients (11 (11.2%) out of 98), cases scored a significantly higher proportion of culture converters than controls (p5 0.03). One case had to withdraw from meropenem-clavulanate due to increased transaminase levels. The results of our study provide: 1) preliminary evidence on effectiveness and safety/tolerability of meropenem-clavulanate; 2) reference to design further trials; and 3) a guide to clinicians for its rationale use within salvage/compassionate regimens. Copyright

Original languageEnglish
Pages (from-to)1386-1392
Number of pages7
JournalEuropean Respiratory Journal
Volume41
Issue number6
DOIs
Publication statusPublished - Jun 1 2013

Fingerprint

Linezolid
meropenem
Multidrug-Resistant Tuberculosis
Clavulanic Acid
Safety
Sputum
Tuberculosis
Extensively Drug-Resistant Tuberculosis
Therapeutics
Drug and Narcotic Control
Transaminases
Case-Control Studies
Guidelines

Keywords

  • Efficacy
  • Linezolid-containing regimens
  • Meropenem-clavulanate
  • Multidrugresistant tuberculosis
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. / De Lorenzo, Saverio; Alffenaar, Jan Wilem; Sotgiu, Giovanni; Centis, Rosella; D'Ambrosio, Lia; Tiberi, Simon; Bolhuis, Mathieu S.; Van Altena, Richard; Viggiani, Piero; Piana, Andrea; Spanevello, Antonio; Migliori, Giovanni Battista.

In: European Respiratory Journal, Vol. 41, No. 6, 01.06.2013, p. 1386-1392.

Research output: Contribution to journalArticle

De Lorenzo, S, Alffenaar, JW, Sotgiu, G, Centis, R, D'Ambrosio, L, Tiberi, S, Bolhuis, MS, Van Altena, R, Viggiani, P, Piana, A, Spanevello, A & Migliori, GB 2013, 'Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB', European Respiratory Journal, vol. 41, no. 6, pp. 1386-1392. https://doi.org/10.1183/09031936.00124312
De Lorenzo, Saverio ; Alffenaar, Jan Wilem ; Sotgiu, Giovanni ; Centis, Rosella ; D'Ambrosio, Lia ; Tiberi, Simon ; Bolhuis, Mathieu S. ; Van Altena, Richard ; Viggiani, Piero ; Piana, Andrea ; Spanevello, Antonio ; Migliori, Giovanni Battista. / Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. In: European Respiratory Journal. 2013 ; Vol. 41, No. 6. pp. 1386-1392.
@article{6ef37ae4ef35495191dc6073924f9763,
title = "Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB",
abstract = "Clinical experience on meropenem-clavulanate to treat tuberculosis (TB) is anecdotal (according to case reports on 10 patients). The aim of our case-control study was to evaluate the contribution of meropenem-clavulanate when added to linezolid-containing regimens in terms of efficacy and safety/tolerability in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases after 3 months of second-line treatment. 37 cases with MDR-/XDR-TB were prescribed meropenem-clavulanate (3 g daily dose) in addition to a linezolid-containing regimen (dosage range 300-1200 mg·day-1 ), designed according to international guidelines, which was prescribed to 61 controls. The clinical severity of cases was worse than that of controls (drug susceptibility profile, proportion of sputum-smear positive and of re-treatment cases). The group of cases yielded a higher proportion of sputum-smear converters (28 (87.5{\%}) out of 32 versus nine (56.3{\%}) out of 16; p=0.02) and culture converters (31 (83.8{\%}) out of 37 versus 15 (62.5{\%}) out of 24; p=0.06). Excluding XDR-TB patients (11 (11.2{\%}) out of 98), cases scored a significantly higher proportion of culture converters than controls (p5 0.03). One case had to withdraw from meropenem-clavulanate due to increased transaminase levels. The results of our study provide: 1) preliminary evidence on effectiveness and safety/tolerability of meropenem-clavulanate; 2) reference to design further trials; and 3) a guide to clinicians for its rationale use within salvage/compassionate regimens. Copyright",
keywords = "Efficacy, Linezolid-containing regimens, Meropenem-clavulanate, Multidrugresistant tuberculosis, Safety, Tolerability",
author = "{De Lorenzo}, Saverio and Alffenaar, {Jan Wilem} and Giovanni Sotgiu and Rosella Centis and Lia D'Ambrosio and Simon Tiberi and Bolhuis, {Mathieu S.} and {Van Altena}, Richard and Piero Viggiani and Andrea Piana and Antonio Spanevello and Migliori, {Giovanni Battista}",
year = "2013",
month = "6",
day = "1",
doi = "10.1183/09031936.00124312",
language = "English",
volume = "41",
pages = "1386--1392",
journal = "European Journal of Respiratory Diseases",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB

AU - De Lorenzo, Saverio

AU - Alffenaar, Jan Wilem

AU - Sotgiu, Giovanni

AU - Centis, Rosella

AU - D'Ambrosio, Lia

AU - Tiberi, Simon

AU - Bolhuis, Mathieu S.

AU - Van Altena, Richard

AU - Viggiani, Piero

AU - Piana, Andrea

AU - Spanevello, Antonio

AU - Migliori, Giovanni Battista

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Clinical experience on meropenem-clavulanate to treat tuberculosis (TB) is anecdotal (according to case reports on 10 patients). The aim of our case-control study was to evaluate the contribution of meropenem-clavulanate when added to linezolid-containing regimens in terms of efficacy and safety/tolerability in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases after 3 months of second-line treatment. 37 cases with MDR-/XDR-TB were prescribed meropenem-clavulanate (3 g daily dose) in addition to a linezolid-containing regimen (dosage range 300-1200 mg·day-1 ), designed according to international guidelines, which was prescribed to 61 controls. The clinical severity of cases was worse than that of controls (drug susceptibility profile, proportion of sputum-smear positive and of re-treatment cases). The group of cases yielded a higher proportion of sputum-smear converters (28 (87.5%) out of 32 versus nine (56.3%) out of 16; p=0.02) and culture converters (31 (83.8%) out of 37 versus 15 (62.5%) out of 24; p=0.06). Excluding XDR-TB patients (11 (11.2%) out of 98), cases scored a significantly higher proportion of culture converters than controls (p5 0.03). One case had to withdraw from meropenem-clavulanate due to increased transaminase levels. The results of our study provide: 1) preliminary evidence on effectiveness and safety/tolerability of meropenem-clavulanate; 2) reference to design further trials; and 3) a guide to clinicians for its rationale use within salvage/compassionate regimens. Copyright

AB - Clinical experience on meropenem-clavulanate to treat tuberculosis (TB) is anecdotal (according to case reports on 10 patients). The aim of our case-control study was to evaluate the contribution of meropenem-clavulanate when added to linezolid-containing regimens in terms of efficacy and safety/tolerability in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases after 3 months of second-line treatment. 37 cases with MDR-/XDR-TB were prescribed meropenem-clavulanate (3 g daily dose) in addition to a linezolid-containing regimen (dosage range 300-1200 mg·day-1 ), designed according to international guidelines, which was prescribed to 61 controls. The clinical severity of cases was worse than that of controls (drug susceptibility profile, proportion of sputum-smear positive and of re-treatment cases). The group of cases yielded a higher proportion of sputum-smear converters (28 (87.5%) out of 32 versus nine (56.3%) out of 16; p=0.02) and culture converters (31 (83.8%) out of 37 versus 15 (62.5%) out of 24; p=0.06). Excluding XDR-TB patients (11 (11.2%) out of 98), cases scored a significantly higher proportion of culture converters than controls (p5 0.03). One case had to withdraw from meropenem-clavulanate due to increased transaminase levels. The results of our study provide: 1) preliminary evidence on effectiveness and safety/tolerability of meropenem-clavulanate; 2) reference to design further trials; and 3) a guide to clinicians for its rationale use within salvage/compassionate regimens. Copyright

KW - Efficacy

KW - Linezolid-containing regimens

KW - Meropenem-clavulanate

KW - Multidrugresistant tuberculosis

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84870747517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870747517&partnerID=8YFLogxK

U2 - 10.1183/09031936.00124312

DO - 10.1183/09031936.00124312

M3 - Article

C2 - 22997218

AN - SCOPUS:84870747517

VL - 41

SP - 1386

EP - 1392

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 6

ER -